Phase 3 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Condition:   Differentiated Thyroid Cancer
Interventions:   Drug: Donafenib;   Drug: Placebo
Sponsor:   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Recruiting

https://ift.tt/2AmzX1F